Consumer Advocate Legal Update : Class Action Lawyers & Attorneys : Khorrami Pollard & Abir Law Firm : Mass Torts, Products Liability

• Email This
• Print
• Comments
• Trackbacks

In January 1999 Merck began their Vioxx Gastrointestinal Outcomes Research (VIGOR) study which compared Vioxx to naproxen, which is the active ingredient in some brand name pain relievers. At the conclusion of the study it was not only apparent that there was a lower incidence of gastrointestinal events in patients being treated with Vioxx , but more significantly there was a higher risk of cardiovascular events in those same patients. On March 27, 2000 Merck issued a public statement explaining those results:

Among patients treated with Vioxx, there was significantly reduced incidence of serious gastrointestinal events compared to patients treated with naproxen…………In addition, significantly few thromboembolic events were observed in patients taking naproxen in this GI outcomes study, which is consistent with naproxen’s ability to block platelet aggregation. This effect on these events had not been observed previously in any clinical studies for naproxen. Vioxx, like all COX-2 selective medicines, does not block platelet aggregation and therefore would not be expected to have similar effects.

Continue reading by clicking here.

• Email This
• Print
• Comments
• Trackbacks

Three reasons why you should read the November KPA Newsletter:

1.  It is the best place to learn about the latest developments in plaintiff litigation.

2.  KPA attorney's Becki Kammerling, Nancy Gardner and Roxanna Tabatabaeepour are this month's featured authors.

3.  See what other top attorneys across the state are reading!

Subscribe to the KPA Newsletter by going here!

• Email This
• Print
• Comments
• Trackbacks

Check out the KPA October 2009 Newsletter which includes articles by associates Katie McSweeney, Abi Gnanadesigan and Deborah Khantamour.

• Email This
• Print
• Comments
• Trackbacks